Inactivation of PI3k/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro

Annals of Hematology

Volumn 89, Issue 11, 2010, Pages 1089-1097

  Liu, Jia Jun ^a   Liu, Wen Da ^a   Yang, Hong Zhi ^a   Zhang, Yong ^a   Fang, Zhi Gang ^a   Liu, Pei Qing ^a   Lin, Dong Jun ^a   Xiao, Ruo Zhi ^a   Hu, Yuan ^a   Wang, Chun Zhi ^a   Li, Xu Dong ^a   He, Yi ^a   Huang, Ren Wei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Leukemia; PI3K Akt; Tanshinone I (Tan I)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; ENZYME PRECURSOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN P85; SURVIVIN; TANSHINONE I; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; PHENANTHRENE DERIVATIVE; TANSHINONE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; UPREGULATION; WESTERN BLOTTING; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HL 60 CELL LINE; K562 CELL LINE; METABOLISM; PATHOPHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; DNA FRAGMENTATION; DRUGS, CHINESE HERBAL; ENZYME ACTIVATION; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR STRUCTURE; PHENANTHRENES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; DITERPENES, ABIETANE; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77956975737     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0996-z     Document Type: Article

References (43)

1. H Boon J Wong 2004 Botanical medicine and cancer: a review of the safety and efficacy Expert Opin Pharmacother 5 2485 2501 10.1517/14656566.5.12.2485 15571467 (Pubitemid 39646512)
2. L Zhou Z Zuo MS Chow 2005 Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use J Clin Pharmacol 45 1345 1359 1:CAS:528:DC%2BD2MXhtlSjtrzL 10.1177/0091270005282630 16291709 (Pubitemid 41643896)
3. AM Wang SH Sha W Lesniak J Schacht 2003 Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo Antimicrob Agents Chemother 47 1836 1841 1:CAS:528:DC%2BD3sXktlymtL4%3D 10.1128/AAC.47.6.1836-1841.2003 12760856 (Pubitemid 36637803)
4. HS Choi DI Cho HK Choi SY Im SY Ryu KM Kim 2004 Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells Arch Pharm Res 27 1233 1237 1:CAS:528: DC%2BD2MXhvFeisw%3D%3D 10.1007/BF02975887 15646797
5. X Wang Y Wei S Yuan G Liu Y Lu J Zhang W Wang 2005 Potential anticancer activity of tanshinone IIA against human breast cancer Int J Cancer 116 799 807 1:CAS:528:DC%2BD2MXosVaqtbk%3D 10.1002/ijc.20880 15849732 (Pubitemid 41099713)
6. SL Yuan YQ Wei XJ Wang F Xiao SF Li J Zhang 2004 Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells World J Gastroenterol 10 2024 2028 1:CAS:528:DC%2BD2cXmslKitrY%3D 15237427
7. CC Su GW Chen JG Lin 2008 Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells Int J Mol Med 22 613 618 1:CAS:528:DC%2BD1cXhsVahsbzF 18949381
8. CY Lee HF Sher HW Chen CC Liu CH Chen CS Lin PC Yang HS Tsay JJ Chen 2008 Anticancer effects of tanshinone I in human non-small cell lung cancer Mol Cancer Ther 7 3527 3538 1:CAS:528:DC%2BD1cXhtlGgsrfF 10.1158/1535-7163.MCT-07- 2288 19001436
9. IT Nizamutdinova GW Lee JS Lee MK Cho KH Son SJ Jeon SS Kang YS Kim JH Lee HG Seo KC Chang HJ Kim 2008 Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules Carcinogenesis 29 1885 1892 1:CAS:528:DC%2BD1cXht1SitLvP 10.1093/carcin/bgn151 18586687
10. C Carlo-Stella C Lavazza A Locatelli L Viganò AM Gianni L Gianni 2007 Targeting TRAIL agonistic receptors for cancer therapy Clin Cancer Res 15 2313 2317 10.1158/1078-0432.CCR-06-2774 (Pubitemid 46698578)
11. P Lunghi A Tabilio PP Dall'Aglio E Ridolo C Carlo-Stella PG Pelicci A Bonati 2003 Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts Leukemia 17 1783 1793 1:CAS:528:DC%2BD3sXntFCitbs%3D 10.1038/sj.leu.2403032 12970778 (Pubitemid 37185254)
12. C Carlo-Stella C Lavazza M Di Nicola L Cleris P Longoni M Milanesi M Magni D Morelli A Gloghini A Carbone AM Gianni 2006 Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand Hum Gene Ther 17 1225 1240 1:CAS:528: DC%2BD28XhtlGktb7P 10.1089/hum.2006.17.1225 17107337 (Pubitemid 44975139)
13. C Carlo-Stella M Di Nicola MC Turco L Cleris C Lavazza P Longoni M Milanesi M Magni M Ammirante A Leone Z Nagy WR Gioffrè F Formelli AM Gianni 2006 The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice Cancer Res 66 1799 1808 1:CAS:528:DC%2BD28XpsVeluw%3D%3D 10.1158/0008-5472.CAN-05-1200 16452241 (Pubitemid 43259966)
14. C Garcia-Echeverria WR Sellers 2008 Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 27 5511 5526 1:CAS:528: DC%2BD1cXhtFWiur3J 10.1038/onc.2008.246 18794885
15. DW Seol 2008 Up-regulation of IAPs by PI-3K: a cell survival signal-mediated anti-apoptotic mechanism Biochem Biophys Res Commun 377 508 511 1:CAS:528:DC%2BD1cXhtlykt7vK 10.1016/j.bbrc.2008.10.021 18929542
16. CW Lindsley SF Barnett ME Layton MT Bilodeau 2008 The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors Curr Cancer Drug Targets 8 7 18 1:CAS:528:DC%2BD1cXitF2ku7s%3D 10.2174/156800908783497096 18288939 (Pubitemid 351237905)
17. J Downward 2004 PI 3-kinase, Akt and cell survival Semin Cell Dev Biol 15 177 182 1:CAS:528:DC%2BD2cXhsFWksr4%3D 10.1016/j.semcdb.2004.01.002 15209377 (Pubitemid 38251646)
18. S Maddika SR Ande S Panigrahi T Paranjothy K Weglarczyk A Zuse M Eshraghi KD Manda E Wiechec M Los 2007 Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy Drug Resist Updat 10 13 29 1:CAS:528:DC%2BD2sXkslahsbw%3D 10.1016/j.drup.2007.01.003 17303468 (Pubitemid 46636381)
19. CS Mitsiades N Mitsiades M Koutsilieris 2004 The Akt pathway: molecular targets for anti-cancer drug development Curr Cancer Drug Targets 4 235 256 1:CAS:528:DC%2BD2cXjs1Gnu78%3D 10.2174/1568009043333032 15134532 (Pubitemid 38560073)
20. P Michl J Downward 2005 Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers Z Gastroenterol 43 1133 1139 1:CAS:528: DC%2BD2MXht1Git7jP 10.1055/s-2005-858638 16220453 (Pubitemid 41584815)
21. G De Santis S Miotti M Mazzi S Canevari A Tomassetti 2009 E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells Oncogene 28 1206 1217 10.1038/onc.2008.470 19151754
22. TM Morgan TD Koreckij E Corey 2009 Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway Curr Cancer Drug Targets. 9 237 249 1:CAS:528:DC%2BD1MXks1Wjs7s%3D 10.2174/156800909787580999 19275762
23. J Qian Y Zou JS Rahman B Lu PP Massion 2009 Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung Mol Cancer Ther 8 101 109 1:CAS:528:DC%2BD1MXjvFSnug%3D%3D 10.1158/1535-7163.MCT-08-0973 19139118
24. JK Shen HP Du M Yang YG Wang J Jin 2009 Casticin induces leukemic cell death through apoptosis and mitotic catastrophe Ann Hematol 88 743 752 1:CAS:528:DC%2BD1MXntlSgsLc%3D 10.1007/s00277-008-0677-3 19139893
25. H Liu K Mihara G Song H Tanaka A Kimura 2007 Interferon-gamma attenuates the survival activity of G-CSF through PI3K/Akt signaling pathway in mouse multipotent progenitor cells Ann Hematol 86 547 555 1:CAS:528: DC%2BD2sXmvVKnur8%3D 10.1007/s00277-007-0308-4 17549474 (Pubitemid 47018472)
26. QY Zhang JH Mao P Liu QH Huang J Lu YY Xie L Weng Y Zhang Q Chen SJ Chen Z Chen 2009 A systems biology understanding of the synergistic effects of arsenic sulfide and imatinib in BCR/ABL-associated leukemia Proc Natl Acad Sci U S A 106 3378 3383 1:CAS:528:DC%2BD1MXivF2jsbs%3D 10.1073/pnas.0813142106 19208803
27. VI Brown AE Seif GS Reid DT Teachey SA Grupp 2008 Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease Immunol Res 42 84 105 1:CAS:528: DC%2BD1MXktlOjtA%3D%3D 10.1007/s12026-008-8038-9 18716718
28. QL Zhang L Wang YW Zhang XX Jiang F Yang WL Wu A Janin Z Chen ZX Shen SJ Chen WL Zhao 2009 The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis Leukemia 23 1507 1514 1:CAS:528: DC%2BD1MXpvF2kurk%3D 10.1038/leu.2009.41 19282831
29. L Guan B Han J Li Z Li F Huang Y Yang C Xu 2009 Exposure of human leukemia NB4 cells to increasing concentrations of selenite switches the signaling from pro-survival to pro-apoptosis Ann Hematol 88 733 742 1:CAS:528:DC%2BD1MXntlSgsbY%3D 10.1007/s00277-008-0676-4 19153735
30. JE Karp JE Lancet 2004 Farnesyltransferase inhibitors (FTIs) in myeloid malignancies Ann Hematol 83 1 S87 88 15124688
31. M Zhang Y Ling CY Yang H Liu R Wang X Wu K Ding F Zhu BN Griffith RM Mohammad S Wang D Yang 2007 A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells Ann Hematol 86 471 481 1:CAS:528: DC%2BD2sXls1Sgs7c%3D 10.1007/s00277-007-0288-4 17396262 (Pubitemid 46863883)
32. JT Jung DH Kim EK Kwak JG Kim TI Park SK Sohn YR Do KY Kwon HS Song EH Park KB Lee 2006 Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas Ann Hematol 85 575 581 1:CAS:528: DC%2BD28XosFWktbo%3D 10.1007/s00277-006-0127-z 16673127 (Pubitemid 44283077)
33. C Bogner M Sandherr M Perker K Weick I Ringshausen C Peschel T Decker 2006 Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells Ann Hematol 85 458 462 1:CAS:528:DC%2BD28Xks1OktLc%3D 10.1007/s00277-005-0076-y 16538501 (Pubitemid 44283112)
34. MH Kang CP Reynolds 2009 Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin Cancer Res 15 1126 32 1:CAS:528:DC%2BD1MXitVOksLg%3D 10.1158/1078-0432.CCR-08-0144 19228717
35. KM Debatin 2004 Apoptosis pathways in cancer and cancer therapy Cancer Immunol Immunother 53 153 197 10.1007/s00262-003-0474-8 14749900 (Pubitemid 38328037)
36. U Gianelli NS Fracchiolla A Cortelezzi C Pellegrini F Savi A Moro MG Grimoldi GL Deliliers G Coggi S Bosari 2007 Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes Ann Hematol 86 185 189 1:CAS:528:DC%2BD2sXhtVamsbs%3D 10.1007/s00277-006-0215-0 17124585 (Pubitemid 46195990)
37. AC Mita MM Mita ST Nawrocki FJ Giles 2008 Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics Clin Cancer Res 5 5000 5005 10.1158/1078-0432.CCR-08-0746
38. L Wang GB Zhou P Liu JH Song Y Liang XJ Yan F Xu BS Wang JH Mao ZX Shen SJ Chen Z Chen 2008 Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia Proc Natl Acad Sci U S A 105 4826 4831 1:CAS:528:DC%2BD1cXkt12qt7k%3D 10.1073/pnas.0712365105 18344322 (Pubitemid 351753831)
39. GB Zhou H Kang L Wang L Gao P Liu J Xie FX Zhang XQ Weng ZX Shen J Chen LJ Gu M Yan DE Zhang SJ Chen ZY Wang Z Chen 2007 Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo Blood 109 3441 3450 1:CAS:528:DC%2BD2sXksFWhsrw%3D 10.1182/blood-2006-06- 032250 17197433 (Pubitemid 46572534)
40. JY Han JY Fan Y Horie S Miura DH Cui H Ishii T Hibi H Tsuneki I Kimura 2008 Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion Pharmacol Ther 117 280 295 1:CAS:528:DC%2BD1cXhtV2it78%3D 10.1016/j.pharmthera.2007.09.008 18048101
41. J Fu H Huang J Liu R Pi J Chen P Liu 2007 Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis Eur J Pharmacol 568 213 221 1:CAS:528:DC%2BD2sXntFKgtLo%3D 10.1016/j.ejphar.2007.04. 031 17537428 (Pubitemid 46976900)
42. D Pérez-Quintanilla S Gómez-Ruiz Z Zizak I Sierra S Prashar I del Hierro M Fajardo ZD Juranić GN Kaluderović 2009 A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes Chemistry 15 5588 5597 10.1002/chem.200900151 19370742
43. Z Darzynkiewicz H Xuan O Masaki 2006 Detection of DNA strand breaks by flow and laser scanning cytometry in studies of apoptosis and cell proliferation (DNA replication) Meth Mol Biol 314 81 93 1:CAS:528:DC%2BD2MXhtFyltrbI 10.1385/1-59259-973-7:081